SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-transfusion-dependent Thalassemia
Conditions
Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome
Trial Timeline
Aug 20, 2019 → Oct 14, 2021
NCT ID
NCT04176653About SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo
SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo is a phase 1 stage product being developed by Silence Therapeutics for Non-transfusion-dependent Thalassemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04176653. Target conditions include Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04176653 | Phase 1 | Withdrawn |
Competing Products
2 competing products in Non-transfusion-dependent Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| SLN124 + Placebo | Silence Therapeutics | Phase 1 | 25 |